PALM BEACH GARDENS, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”) (NASDAQ: GEG), today announced plans to release financial results for the fiscal quarter ended March 31, 2025, after the close of market trading on Wednesday, May 7, 2025.
Company to Host Conference Call & Webcast
Great Elm will also host a conference call and webcast on Thursday, May 8, 2025, at 8:30 a.m. Eastern Time to discuss its fiscal 2025 third quarter financial results.
All interested parties are invited to participate in the conference call by dialing +1 (877) 407-0752; international callers should dial +1 (201) 389-0912. Participants should enter the Conference ID 13746971 if asked.
A copy of the slide presentation that will be referenced during the conference call can be found here.
The conference call will be webcast simultaneously and can be accessed here.
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.09 |
Daily Volume: | 1,230 |
Market Cap: | US$61.130M |
February 05, 2025 November 11, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load